hot news

Shaanxi International Medical Exchange Promotion Association (SXIMEA) successfully held the 2022 Northwestern Anticancer Drug Standardization Application Academic Symposium in Shaanxi Province.

On February 4, 2023, the 2022 Northwestern Anticancer Drug Standardization Application Academic Symposium, hosted by the SXIMEA, was successfully held on an online platform. This conference featured several well-known domestic experts and scholars who were invited to discuss new standards for the standardized application of anticancer drugs in the field of oncology.

Professors Xiaoming Hou from the First Hospital of Lanzhou University, Hongxia Li from the First Affiliated Hospital of Xi'an Jiao Tong University, and Jiang Liu from the Xinjiang Uygur Municipal People’s Hospital jointly served as the conference chairs and delivered the opening speeches for this event.

In the first session, Professor Luhai Yu from the Xinjiang Uygur Municipal People’s Hospital served as the moderator. Professor Weiyi Feng from the First Affiliated Hospital of Xi'an Jiao Tong University delivered an insightful presentation on "Clinical Application Management Practices for Anticancer Drugs."

During the discussion session, Professor Peixi Zhao from Shaanxi Provincial Cancer Hospital served as the moderator. Professors Yuzhong Jin from Gansu Provincial Cancer Hospital, Yafeng Wang from Qinghai Provincial People's Hospital, Shengjun Zhao from the Traditional Chinese Medicine Hospital at Xinjiang Uygur Municipal, and Liting Xu from Xi'an International Medical Center Hospital participated in a joint discussion.

In the second session, Professor Xiaoli Wang from the First Affiliated Hospital of Xi'an Jiao Tong University served as the moderator. Professor Xingang Wei from Shaanxi Provincial People's Hospital delivered an insightful presentation on " Interpretation of National Negotiations on Xi'an's Drug Health Insurance Policy."

During the discussion session, Professor Wensheng Zhang from the Affiliated Cancer Hospital of Xinjiang Medical University served as the moderator. Professors Shaohua Cao from Yan'an University Affiliated Hospital, Nan Zhang from the First Affiliated Hospital of Xinjiang Medical University, Yin Wu from Xi'an Gaoxin Hospital, and Xiaolei Liu from the First Affiliated Hospital of the Air Force Medical University (Xijing Hospital) participated in a joint discussion.

In the third session, Professor Xiaoming Hou from the First Hospital of Lanzhou University served as the moderator. Professor Zhigang Han from Xinjiang Cancer Hospital delivered an insightful presentation on "Review of ALK-TKI Targeted Therapy from First to Third Generation."

During the discussion session, Professors Hongliang Zhang from the Traditional Chinese Medicine Hospital at Xinjiang Uygur Municipal, Reguli Mi from the Eighth Affiliated Hospital of Xinjiang Medical University, Wang Yan from the General Hospital of Ningxia Medical University, and Mingrui Xie from Yulin Second Hospital participated in a joint discussion.

In the fourth session, Professor Jiang Liu from t the Xinjiang Uygur Municipal People’s Hospital served as the moderator. Professor Yu Yao from the First Affiliated Hospital of Xi'an Jiao Tong University delivered an insightful presentation on "Latest Progress in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer Patients."

During the discussion session, Professors Siyun He from Lanzhou Second People's Hospital, Liu Juanni from Shaanxi Nuclear Industry 215 Hospital, and Haifeng Ouyang from Xi'an International Medical Center Hospital participated in a joint discussion.

At the end of the conference, Professor Xiaoming Hou from the First Hospital of Lanzhou University provided a summary of the event.

The conference engaged in discussions and exchanges through online academic presentations and case discussions by well-known domestic experts and scholars in the field. It aimed to understand and track the latest developments in the standardized application of anticancer drugs, providing a comprehensive and fresh perspective for professionals in the field of oncology. This event helped lay the foundation for further standardizing the application of new standards for anticancer drugs.